Leuko is pioneering a groundbreaking technology known as PointCheck™, which is designed for non-invasive monitoring of white blood cell levels, specifically targeting severe neutropenia. This innovative device operates by shining light into the skin around the fingernail to image blood cells flowing through superficial capillaries. By utilizing advanced artificial intelligence algorithms, PointCheck™ can quickly assess whether white blood cell levels are dangerously low, enabling patients, particularly those undergoing chemotherapy, to monitor their health without the discomfort and complications associated with traditional blood draws. This capability allows for more frequent testing, which can lead to timely interventions and improved clinical outcomes.

The PointCheck™ device is particularly significant for immunosuppressed patients, as it helps identify elevated risks of infection, a critical concern for those with compromised immune systems. By facilitating at-home monitoring, PointCheck™ empowers patients to take proactive steps in their healthcare, potentially preventing severe infections before they occur. Although still in the investigational stage and not yet available for sale, the technology has garnered attention for its potential to enhance the quality of life for patients while also reducing healthcare costs.

United States

Leuko is developing the first non-invasive white blood cell device. White blood cell assessment is a first-line indicator for various medically-relevant situations, ranging from chemotherapy management to the detection of life threatening infections worldwide. This test is currently invasive and not readily accessible - it requires patient travel, blood draws and laboratory infrastructure. Based on MIT research, Leuko is re-imagining the way to perform these tests without extracting blood and in a portable device.

Leuko

Company Details